Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OK, but could you please tell us abut penny with " perfect " fundamentals ( financial statements) ,not to many out there!!!??
Smooth, steady - we shall see what is the direction in the next hour!!!
:))))
Good day - today! There was a play for everybody, flippers, bashers, longs....! The chart looks good, a lot of attention here ........., maybe some news (soon)! The direction is north, hold the positions:) IMO
Good!!! You made you point!!! Nobody will use this one in a retirement portfolio! Now let's try to make some money this days!!!!:))
What is wrong man? You have been writing about this stock for long time - 6-8 months???? Are you ok???
It has been all day long??? When you are gonna get tired :))))???
Stable, consistent and promising!!!!! Not bed, not bed at all:)
This baby is getting popular!!!
It will come, but let's build more confidence - than push! There ara a lot of people sill watching, they will come and play soon!!
Don't be so demanding :)) this levels are perfect for now! We'll see! Good play!
Too much talking!!!!!
Control plus uptrend. - good job!
Humm, they keep the stock on very tight leash!
No problemo!!!:)
I am "IN"!! There is not too much outside promo pressure here, that's why I like it! We shall see what Is going to happen, but I am positive ........!!!
Talking about the PUMP - it was all over two weeks ago!!!
There are no promo e_mails, no news and they keeping it in range so, something is going on. It does not look as typical pump/dump!! If it was would be a history by now!
Technically correct!!! Good job!
The EDGAR system hours of operation for submitting files are 6:00 a.m. to 10:00 p.m. Eastern Time, weekdays, excluding Federal Holidays. Files submitted after 5:30 p.m. Eastern (with the exception of Section 16 filings) will receive the next business day's filing date.
10:00 p.m. I think!
The balloon has't blow up yet, just released some air! We'll see how is going to act tomorrow!
Trampoline has been build on these levels! Let's see, if we can jump!!!
BMSN ~ (trading at .0035 cents) Our Top Rated Stem Cell Play has been on Fire ever since we started Covering it on 1/11/13 at .0013 cents per share.. BMSN closed up another 52% yesterday at .0035 cents after hitting an intra day high of .0038 cents.. Congrats Members on Making Mad Bank on BMSN the past few days..
BMSN is up 170% overall since we announced it as our "New Vip Pick".. BMSN traded 325mm Friday and 317mm yesterday after we announced it as our New Vip Pick so as you can see its ramping up..
BMSN is Pending News today and it could very likely come after hours.. The company's 10K is due out today any time and we feel it could most likely come after hours since it is not on the wire yet this a.m...
Remember Members BMSN is a top tier OTCQB Stem Cell play that is a fast mover so act fast on this one and enjoy the ride.. Many of our Members have already emailed us and thanked us for this Top Rated gem of a pick and we are glad to see our Members making serious Bank on BMSN..
~~Below is our Previous Report and Alert again on BMSN in case you missed it the past few days~~
BMSN ~ Our Top Stem Cell play with pending FDA IND Application News, Research & Safety Data News, Phase I/II trial update News as well as Merger News closed up 77% from our alert on Friday with 325mm shares traded..
BMSN ~ Is now the "Hottest Biotech and Stem Cell Play" in the Otc Markets and its getting ready to Breakout Today on the Opening Bell at .0024 cents therefore Creating a Monster Run to the Upside..
Members Do Not Miss out on BMSN... BMSN looks to be the next Top Biotech and Stem Cell play in the market.. Our last Biotech Pick (AMBS) ran 2,400% short term.. We were the Exclusive marketing firm behind AMBS starting from September until December 2012 when it ran from .005 to .19 cents per share (check stockpromoters.com as proof).. Well our New Vip Pick and Top Biotech Stem Cell play is now BMSN..
BMSN ~ Became our New Vip Pick on Friday, January 11th 2013 and the Top Stem Cell Biotech Stock when it was trading at .0013 cents.. As we told all our Members we felt BMSN was going to be our next AMBS type play and so far we have been exactly right..
Members if you recall AMBS was our last Biotech Vip Pick at .005 cents and it ran to a high of .19 cents recently.. BMSN is our New Biotech Vip Pick and its chart is screaming breakout right now.. BMSN is Pending to Announce FDA IND Application News for its Drug, Safety & Research News on its Drug and Merger News so act fast on this one Members..
BMSN ~ Must Read Biotechnology Study for its Latest Science and Stem Cell Technology.. Title is "Exogenous endothelial cells as accelerators of hematopoietic reconstitution"..
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf
Conclusion: While significant advances have been made in the use of growth factors for stimulation of hematopoietic reconstitution, overall efficacy of this approach is limited. Cell therapy offers the possibility of administering an “intelligent” therapeutic which addresses the hematopoietic needs of the host in real-time. Autologous SVF therapy, such as the HemXellerate product, offers the possibility of delivering a heterogenous population of endothelial cells, mesenchymal stem cells, and other potential cells of interest. Given the established safety and ease of autologous SVF administration, it is anticipated that the proposed procedure will be rapidly adopted by the market.
BMSN is a Biotechnology company developing Regenerative Medicine therapies..
The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications. Regen BioPharma, Inc., a subsidiary of BMSN, is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
BMSN is Breaking Out exactly as we said it would and the Company's 10K is due out on January 15th so act fast on this one Members..
Many investors and traders as well as news sources are speculating the company will be releasing its FDA IND Application, Research & Safety Data News and or its Merger this week with the Company's 10K due out.. This one could really orbit with all things lining up here..
Many BMSN Traders are calling for a fast run right to the 200 day moving average at .0038 or much higher beginning of this trading week.. The chart is screaming Bullish right now..
Make sure to Get ready this morning and pull up BMSN on your quotes and charts cause this one looks to run high short term..
BMSN has Assessed over 20,000 Stem Cell related issued Patents, narrowed down to 2000 Patents with commercial applicability, and further identified 30 Patents available for Licensing.
BMSN seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies. HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally." Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN recently announced Thomas E. Ichim, PhD (view here) has joined the management team of its Regen BioPharma, Inc. subsidiary as Chief Scientific Officer and Director of Research.
Regen BioPharma is the company's translational medicine platform for the rapid commercialization of stem cell therapies. Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune. David Koos, Chief Executive Officer of BMSN, stated: "Dr. Ichim is a seasoned biotechnology executive with a track record of scientific excellence. We now have a world-class team to lead our efforts to commercialize stem cell therapies."
BMSN ~Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
BMSN Also Developing Two Solutions for Restoring Blood Production That Lack the Adverse Effects of Current Bone Marrow Stimulating Growth Factors
SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.
The results of Regen's study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN ~ Recently announced that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing.
Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study."
BMSN ~ Breaking Merger News is Pending.. The CEO of BMSN has mentioned its Pending to Announce Merger News with its Majority Owned Subsidiary Entest BioMedical, Inc (OTCBB: ENTB)..
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of BMSN.. The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues. Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer.
The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment. Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 BB will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.
ExclusiveStockAlerts (ESA) looks for the right plays at the right time and best of all we look for undervalued plays…
ESA is an exciting online financial terminal where readers, traders and investors can come to discover new ideas, opportunities, situations and news. ESA goal is finding the Undervalued Gem Plays or the Next Emerging Growth Stock that might be unnoticed by Wallstreet. ESA is also a well-respected marketing and research firm that uses its strategic corporate communication services to increase investor awareness of Fast Emerging Growth Companies..
GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY: We are engaged in the business of marketing and advertising companies for monetary compensation. By viewing or using ExclusiveStockAlerts.com (ESA) you hereby fully agree to our Legal Disclaimer (http://exclusivestockalerts.com/disclaimer) and our Privacy Policy. Never invest into a stock discussed on our website or the ESA newsletter unless you can afford to lose your entire investment. This is not a solicitation to buy or sell a security. This is for entertainment purposes only. Please consult with a certified financial advisor before making any investment decisions. ESA and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the ESA web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock. ESA has been retained by an unrelated third party for marketing and advertising services intended to increase investor awareness of BMSN. ESA has not yet received, to date, any funds for marketing and advertising services intended to increase investor awareness of BMSN. However ESA expects to recieve a total of five thousand dollars for a 1 week marketing and advertising services intended to increase investor awareness of BMSN. In future, ESA will disclose any future compensation. Some of the services performed have included profiling the company on the ESA website and issuing opinions concerning this new profile in newsletters. Anyone viewing the ESA website or its newsletters should assume the hiring party or affiliates of the hiring party own shares of BMSN, which they plan to liquidate. Further, it must be understood that the liquidation of those shares may or may not negatively impact the share price. ESA has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copy-writing services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding BMSN.
Release of Liability: Through use of this website viewing or using you agree to hold ESA and its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.The information contained in the website and in any reports is provided on an "as-is" basis and has not been verified by us. All information on profiled companies is provided by such companies, or is available from public sources and no representation, warranty or guaranty is made as to its accuracy or completeness. ESA is under no obligation to update any information or opinions contained herein. Investors should not rely solely on the information presented herein, but rather use such information as a starting point for doing additional independent research on the profiled companies in order to form investment strategies and decisions. Neither ESA nor any of its owners, operators, or affiliates shall be liable to any subscriber or reader for any losses or damages arising from the use of any information contained herein, caused in whole or part by ESA in procuring, compiling, interpreting, reporting, or delivering any of the information contained herein or otherwise delivered. Since ESA receives compensation from, and its owners, operators and affiliates may hold stock in, the profiled companies, there is an inherent conflict of interest in ESA statements and opinions and such statements and opinions cannot be considered independent. ESA and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled companies. ESA services are often paid for using free-trading shares. ESA and/or its owners, operators and affiliates may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; ESA will not advise when it or its affiliates decide to sell. Investors must make all investment decisions based on their own judgment of the market and the particular securities. Information presented by ESA may contain "Forward-Looking-Statements" (F-L-S) within the meaning of Section"27A"of the"Securities-Act-of-1933"and"Section-21E-of-the-Securities-Exchange-Act of 1934."Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be "F-L-S." F-L-S are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. F-L-S may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating that certain actions "may," "could," or "might" occur.We encourage our readers to invest carefully and review all forms of investments and read investor information. More information on the profiled companies may be found from the Securities Exchange Commission ("SEC") at http://www.sec.gov, the Financial Industry Regulatory Authority (FINRA) at: http://www.finra.org and the NASDAQ at: http://www.nasdaq.com. Readers can review all public filings by companies at the SEC's EDGAR page. FINRA publishes information on how to invest carefully on its website. Our website may provide hyperlinks to third party websites or access to third party content. ESA does not control, endorse or guaranty content found on such sites, is not responsible for nay content, associated links, resources or services associated with such third party site, and is not liable for any loss or damages associated with the use of such site or content. Links and access to these sites are provided for your convenience only.Disclaimer of Warranties and Limitation of Liability: This site is provided by ExclusiveStockAlerts.com (ESA) on an "As Is" and "As Available" basis. ESA makes no representation of warranties of any kind, Express or Implied, as to the operations of this site or the information, content, materials, or products included on this site. You expressly agree that your use of this site is at your sole risk. To the the full extent permissible by applicable law, ESA Disclaims all warranties express or implied, but not limited to, implied warranties of merchantability and fitness for a particular e-mail sent from ESA are free of viruses or other harmful components. ESA, its members, managers, owners, agents and employees will not be liable for any damages of any kind arising from the use of this site, including, nut not limited to direct, indirect, incidental, punitive, and consequential damages, certain state laws do not allow limitations on implied warranties or the exclusion or limitation of certain damages. If these laws apply to you, some or all of the above disclaimers, exclusions, or limitations may not apply to you and you might have additional rights.
ExclusiveStocks • 7378 W. Atlantic Blvd #336 • Margate, FL 33063
Subscribe | Unsubscribe | Send to a Friend | Preferences | Report Spam
Powered by MyNewsletterBuilder
GO!!!!
It is completely dead here today???
There's 80-150% gain in this stock, right now, IMO. Maybe more!!!!
They will!!! Hope so!!
This one going nowhere , without BC players!
Let's close over 0.06
No need for speed!!!
Let's do the "love game" first - than we will get the best " s...x":)
I've got my position and patiently waiting! " the lot has been bought, let's build the house"!
AMBS ~ We're expecting a nice Bounce & Reversal in AMBS. AMBS is trading around its Major Support in the .03's today and on the verge of Forming a solid bottom and reversal. Plus there is news out today on a big investor purchasing a promissory note from the company at .05 cents today which tells us AMBS is clearly undervalued at these ranges today.
Plus Members, don't forget AMBS filed an 8-K stating Dr. Joseph Rubinfeld, Co-founder of AMGEN, purchased 1mm shares at .01 cents in a convertable note so that tells us the Co-Founder of "AMGEN" himself feels AMBS is a great company and worth much more than where its currently trading at today. Furthermore Dr. Joseph Rubinfeld, Co-founder of AMGEN has now joined the AMBS Advisory board which is huge and stated that AMBS drug "MANF" has the commercial potential to become a blockbuster drug.
AMBS ~ See the Major Support in place on the chart by clicking http://stockcharts.com/c-sc/sc?s=AMBS&p=60&yr=0&mn=2&dy=0&i=p91557247447&a=281939446&r=1352385806859
We're continuing to cover AMBS as our Top Biotech of 2012 and will be highlighting somethings on it in the coming days. Congrats to those of you that have been consisting making money with us and our Our Exclusive Pick "AMBS"
Members our group & network sites have been Exclusively covering "AMBS" for over a month now and we've been saying we felt AMBS was a way undervalued Biotech play. Well AMBS has been breaking out and our members are reaping the rewards of our Exclusive Play "AMBS"
----------
Members, here's a recent recap Alert on Our Exclusive Pick "AMBS" ..... AMBS is working to file its new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF with the Food and Drug Administration. Don't forget AMBS filed an 8-K stating Dr. Joseph Rubinfeld, Co-founder of AMGEN, purchased 1mm shares at .01 cents in a convertable note so that tells us the Co-Founder of "AMGEN" himself feels AMBS is a good play and worth more.
AMBS also showed up on the Nasdaq Reg-Sho list which means someone been "SHORTING AMBS" and trying to hold the stock down. Well we feel this blockbuster drug news today will force a short squeeze on AMBS short term therefore breaking the stock out. Don't miss this news and opportunity Members!
Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
"Protein misfolding and aggregation plays a significant role in a wide range of human diseases, including very common diseases such as Parkinson's and Alzheimer's, as well as many rare and ultra-rare diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "MANF has a unique ability to mediate protein folding in an extracellular fashion, making it potentially an ideal biologic drug candidate for a wide range of human conditions. Parkinson's continues to remain the Company's primary focus, especially in light of recently announced data where MANF demonstrated superiority over GDNF in a neurorestoration animal model of Parkinson's disease. However, the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's utility in diseases that have much smaller patient populations, and we will make a concerted effort to focus on rare and ultra-rare diseases when reviewing the results. This strategy may afford the Company an accelerated pathway to commercialization by identifying therapeutic applications for MANF that would require few small clinical trials. Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."
The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
----------
Form 8-K for AMARANTUS BIOSCIENCES, INC.
News from 31-Oct-2012. Item 8.01. Other Events
On October 26, 2012, Amarantus BioSciences, Inc. issued a Convertible Promissory Note to Dr.Joseph Rubinfeld, co-founder of Amgen, in the principal amount of $10,000.00. The Note bears interest at the rate of six percent (6%) per annum until paid in full and is convertible into shares of Amarantus common stock at the price of $0.01 per share upon ten (10) days written notice to Amarantus. Dr. Joseph Rubinfeld has submitted a conversion notice to convert his entire note into common stock, for a total 1,000,000 common shares, to be issued within 10 days. The principal amount of the Note is not material to Amarantus and if converted, the number of shares issued in conversion would be less that one percent (1%) of the outstanding shares of Amarantus.
----------
AMBS ~ Other Blockbuster News... AMBS just received positive behavioral efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease.
The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
SUNNYVALE, Calif., Oct. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
In Parkinson's disease, the nigro-striatal network (substantia nigra – striatum) is compromised due to the degeneration of dopaminergic neurons in the substantia nigra, which results in dopaminergic nerve terminal retraction from the striatum towards the substantia nigra. This leaves the striatum with inadequate dopamine levels, which in turn causes motor function deficits and other symptoms. Currently approved drugs that relieve symptoms focus on replacing the dopamine lost in the striatum; however, the symptom relief is temporary and the drugs typically lose their ability to abate symptoms roughly 7-10 years after the initiation of drug therapy. There are no approved therapies that focus on re-innervating the striatum by protecting dopaminergic neuron cell bodies in the substantia nigra while restoring dopaminergic innervation in the striatum.
In rat studies conducted by an independent academic laboratory contracted by Amarantus, 6-OHDA was injected directly into the striatum on one side of each rat's brain, causing their dopaminergic terminals to retract from the striatum towards the substantia nigra, and creating Parkinson's-like behavioural symptoms that were quantified by counting the number of times the rats turned in a circle in the same direction (behavioural deficits) in a given 120 minute period of time. MANF and GDNF were delivered directly into the substantia nigra of separate groups of rats 2 weeks following the administration of the 6-OHDA, in order to mimic as closely as possible in rats the treatment setting in humans where treatment would be administered after an extended timeframe following the initiation of dopaminergic nerve terminal retraction, each at the optimal dosing level of 10 micrograms. Four weeks following MANF treatment into the substantia nigra, behavioural deficits were reduced by ~43%, and six weeks following MANF treatment, behavioural deficits were reduced by ~53%; four weeks following GDNF treatment into the substantia nigra, behavioural deficits were reduced by ~16%, and six weeks following GDNF treatment, behavioural deficits actually increased by ~20%.
"The data obtained in this study provide clear evidence that MANF had a strong positive and restorative effect on the behaviour of animals in this pre-clinical Parkinson's disease study when delivered to the substantia nigra, whereas GDNF had no such effect," said John W. Commissiong PhD, Chief Scientist at Amarantus and former Head of the Neurotrophic Factors Group at the National Institutes of Health. "The localization of the drug treatment in this study is critical because, as Parkinson's disease progresses, dopaminergic nerve terminals typically retract from the striatum towards their cell bodies in the substantia nigra, resulting in the disruption of the basal ganglia network that is responsible for proper motor function. Translated, the longer you have Parkinson's disease, the less likely a neurotrophic factor will work when delivered to the striatum because there are fewer dopaminergic nerve terminals remaining to act on, and so neurotrophic factor drugs for later-stage patients will likely work best when delivered to the substantia nigra. No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
Neurotrophic factors have been promising drug candidates for Parkinson's disease for over two decades because they have special biological properties that allow them to selectively protect certain neurons. Large biotechnology companies and leading academic investigators have conducted a number of clinical trials on GDNF in Parkinson's disease first initiated in 1996, at an estimated total cost of over $400M, where GDNF has shown promise as a disease-modifying treatment. However, technological limitations of delivering neurotrophic factors to the brain, limitations that Amarantus believes have been resolved by researchers in academia and industry, have delayed the translation of the underlying biology of neurotrophic factors into approved medicines. A unique drug such as MANF that potentially acts by re-innervating the striatum when delivered to the substantia nigra, combined with newly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.
"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."
----------
Members we feel AMBS potential Parkinsons Disease cure looks to be very big. AMBS owns and is developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis. MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. AMBS also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.
Make sure to tell your friends who are not signed up to go ahead and sign up now to http://exclusivestockalerts.com/. You can forward this email to your contacts to facilitate the process. As our community grows, we all benefit. Let them know "ExclusiveStocks"wants to hear from them..
The Official "ExclusiveStocks" Newsletter
By viewing or using Exclusivestockalerts.com (ExclusiveStocks ) you hereby fully agree to ourLegal Disclaimer (http://exclusivestockalerts.com/disclaimer) and our Privacy Policy. Never invest into a stock discussed on our website or the ExclusiveStocks newsletter unless you can afford to lose your entire investment. This is not a solicitation to buy or sell a security. This is for entertainment purposes only. Please consult with a certified financial advisor before making any investment decisions. ExclusiveStocks and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the ExclusiveStocks web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock. ExclusiveStocks has been retained by an unrelated third party for marketing and advertising services intended to increase investor awareness of AMBS. ExclusiveStocks has received, to date, a total of thirty nine thousand five dollars for marketing and advertising services intended to increase investor awareness of AMBS. Some of the services performed have included profiling the company on the ExclusiveStocks website and issuing opinions concerning this new profile in newsletters. In future, ExclusiveStocks will disclose any future compensation. Anyone viewing the ExclusiveStocks website or its newsletters should assume the hiring party or affiliates of the hiring party own shares of AMBS, which they plan to liquidate. Further, it must be understood that the liquidation of those shares may or may not negatively impact the share price. ExclusiveStocks has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copy-writing services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding AMBS.
ExclusiveStocks • 7378 W. Atlantic Blvd #336 • Margate, FL 33063
Subscribe | Unsubscribe | Send to a Friend | Preferences | Report Spam
Powered by MyNewsletterBuilder
Our Pick: AMBS ~ Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board. We are batting 1,300% on AMBS so make sure to read below:
Members our site and group are the only ones that have been "EXCLUSIVELY" covering AMBS since September and now its very easy to spot all the copycat sites trying to ride our cotails and cover AMBS. Just remember we were screaming at the top of our lungs from September all the way till now that AMBS looked to be a blockbuster Biotech drug company and that we felt AMBS would show our Members Blockbuster type returns...Well guess what? We showed you this stock move from .005 to .02 in September and now once again from .005 to .055 moving over 1,300% combined Returns!
Amgen Co-Founder Dr. Joseph Rubinfeld Joins the AMBS Advisory Board today and stated,"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. MANF has the commercial potential to become a blockbuster drug."
Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
"Clearly, Dr. Rubinfeld joining the Advisory Board is a tremendous endorsement for the Company at this critical juncture in our growth cycle," said Gerald E. Commissiong, President & CEO of Amarantus. "The Advisory Board is now well populated with extremely talented experts in the various fields that are necessary to position us for growth: science, investment banking/M&A, business development and regulatory affairs. We now intend to leverage these relationships to fill out the management team and Board of Directors with development expertise and Big Pharma experience in order to attract the capital necessary to advance our development programs towards key value inflexion milestones."
Dr. Rubinfeld is the fourth member of Amarantus' Advisory Board. The bios of the other members of the Company's Advisory Board are below:
Owen Garrick, MD MBA
Dr. Owen Garrick currently serves as the President & Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Mark Benedyk, PhD
Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Dr. Benedyk is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University's Graduate School of Business, and the University of Virginia Darden School of Business.
Clinton Allen, MSc
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
IMPORANT MEMBERS: Make sure to have your friends, associates, business partners and family members all sign up for our FREE "Exclusive Vip Alerts" so they too can benefit from our AMBS alerts and the next 1,300% winner like AMBS. Feel free to sign them up yourself for FREE right now at: http://www.exclusivestockalerts.com
Make sure to tell your friends who are not signed up to go ahead and sign up now to http://exclusivestockalerts.com/. You can forward this email to your contacts to facilitate the process. As our community grows, we all benefit. Let them know "ExclusiveStocks"wants to hear from them..
The Official "ExclusiveStocks" Newsletter
By viewing or using Exclusivestockalerts.com (ExclusiveStocks ) you hereby fully agree to ourLegal Disclaimer (http://exclusivestockalerts.com/disclaimer) and our Privacy Policy. Never invest into a stock discussed on our website or the ExclusiveStocks newsletter unless you can afford to lose your entire investment. This is not a solicitation to buy or sell a security. This is for entertainment purposes only. Please consult with a certified financial advisor before making any investment decisions. ExclusiveStocks and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the ExclusiveStocks web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock. ExclusiveStocks has been retained by an unrelated third party for marketing and advertising services intended to increase investor awareness of AMBS. ExclusiveStocks has received, to date, a total of thirty nine thousand five dollars for marketing and
advertising services intended to increase investor awareness of AMBS. Some of the services performed have included profiling the company on the ExclusiveStocks website and issuing opinions concerning this new profile in newsletters. In future, ExclusiveStocks will disclose any future compensation. Anyone viewing the ExclusiveStocks website or its newsletters should assume the hiring party or affiliates of the hiring party own shares of AMBS, which they plan to liquidate. Further, it must be understood that the liquidation of those shares may or may not negatively impact the share price.
ExclusiveStocks has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copy-writing services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding AMBS.
ExclusiveStocks • 7378 W. Atlantic Blvd #336 • Margate, FL 33063
Subscribe | Unsubscribe | Send to a Friend | Preferences | Report Spam
Powered by MyNewsletterBuilder
Exclusive stocks - promo!!!